BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tapinarof readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tapinarof\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05981118-1783@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tapinarof: Phase 2/3 readout est. (NCT05981118)
DESCRIPTION:Tapinarof\, phase 2/3\, Psoriasis.\nStudy: Comparison of Post-I
 nflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant
 )\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tapinarof#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05981118
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265479-1783@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tapinarof: Phase 3 readout est. (NCT07265479)
DESCRIPTION:Tapinarof\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Inv
 estigate Safety and Efficacy of Tapinarof Cream\, 1% in Participants Ages 
 3 Months to < 24 Months With Atopic Dermatitis\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tapi
 narof#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07265479
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06661213-1783@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tapinarof: Phase 1 readout est. (NCT06661213)
DESCRIPTION:Tapinarof\, phase 1.\nStudy: Tapinarof for Cutaneous Lupus Eryt
 hematosus\nEstimated primary completion: November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tapinarof#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06661213
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561321-1783@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tapinarof: Phase 2 readout est. (NCT06561321)
DESCRIPTION:Tapinarof\, phase 2.\nStudy: Study to Evaluate the Safety and E
 fficacy of Tapinarof in Adults With Palmoplantar Keratoderma\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tapinarof#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06561321
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-1783@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Tapinarof: Phase 4 readout est. (NCT07352566)
DESCRIPTION:Tapinarof\, phase 4\, Atopic Dermatitis.\nStudy: Utilization of
  a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary comp
 letion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tapinarof#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07352566
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
